INDB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Independent Bank Corp (INDB) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong financial growth and positive analyst outlooks, the lack of immediate trading signals, hedge fund selling activity, and mixed analyst ratings suggest a cautious approach. Holding the stock or waiting for a better entry point may be more prudent.
The stock's technical indicators are mixed. The MACD is positive but contracting, RSI is neutral at 46.946, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 78.561, with resistance at 81.267 and support at 75.855. No clear strong upward or downward trend is evident.
Strong financial performance with Q1 revenue up 41.9% YoY and net income up 50.57% YoY.
Analysts have initiated coverage with an Overweight rating and price targets as high as $
The company operates in a desirable Boston market with strong deposits and fee income sources.
Hedge funds are selling, with a significant increase in selling activity (496.52% over the last quarter).
Mixed analyst ratings, with some firms maintaining Underweight or Neutral ratings due to concerns about competition and credit uncertainty.
Q1 EPS missed estimates by $0.01, which may weigh on investor sentiment.
The company has shown strong growth trends. In Q1 2026, revenue increased by 41.9% YoY to $252.7 million, and net income rose to $79.92 million, up from $44.42 million YoY. However, the EPS of $1.63 missed estimates by $0.01. The previous quarter (2025/Q4) also demonstrated robust growth with revenue up 44.43% YoY and net income up 50.57% YoY.
Analyst sentiment is mixed. Stephens initiated coverage with an Overweight rating and an $88 price target, citing strong profitability metrics and market positioning. Barclays raised its price target to $82 but maintained an Underweight rating, citing concerns about competition and credit uncertainty. Piper Sandler assumed coverage with a Neutral rating and a reduced price target of $84.
